Intec Pharma, which is developing an improved delivery method of carbidopa/levodopa for Parkinson's disease, filed on Tuesday with the SEC to raise up to $46 million in a US initial public offering.
Intec Pharma trades on the Tel Aviv Stock Exchange under the symbol INTP with a market cap of about $44 million.
Biotie Therapies (BITI), a Parkinson's disease biotech that is listed in Finland, plans to float its shares in the US later this week. Cynapsus Therapeutics (CYNA), a Parkinson's biotech currently traded on the Toronto Stock Exchange, set terms on Tuesday to raise $64 million in a US offering next week.
The Jerusalem, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol INTP.RC. Intec Pharma initially filed confidentially on April 7, 2014. Maxim Group LLC and Roth Capital are the joint bookrunners on the deal. No pricing terms were disclosed.
